VNRX Volitionrx Ltd
Price (delayed)
$0.655
Market cap
$60.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.4
Enterprise value
$60.19M
Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to
Highlights
The revenue has surged by 88% year-on-year and by 23% since the previous quarter
The gross profit has soared by 88% YoY and by 23% QoQ
The quick ratio has plunged by 81% YoY and by 47% from the previous quarter
The equity is down by 40% since the previous quarter
Key stats
What are the main financial stats of VNRX
Market
Valuations
Earnings
Shares outstanding
92.1M
Market cap
$60.33M
Enterprise value
$60.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
55.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.64
Revenue
$976,516
EBIT
-$32.15M
EBITDA
-$30.78M
Free cash flow
-$17.69M
Per share
Balance sheet
Liquidity
EPS
-$0.4
Free cash flow per share
-$0.21
Book value per share
-$0.26
Revenue per share
$0.01
TBVPS
$0.15
Total assets
$13.07M
Total liabilities
$35.97M
Debt
$5.86M
Equity
-$21.81M
Working capital
-$23.63M
Debt to equity
-0.27
Current ratio
0.24
Quick ratio
0.2
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
-3,152%
Gross margin
100%
Net margin
-3,320.1%
Operating margin
-3,355.7%
Return on assets
-165.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-3,292.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VNRX stock price
How has the Volitionrx stock price performed over time
Intraday
-5.32%
1 week
0.46%
1 month
9.72%
1 year
-46.31%
YTD
-8.65%
QTD
8.26%
Financial performance
How have Volitionrx's revenue and profit performed over time
Revenue
$976,516
Gross profit
$976,516
Operating income
-$32.77M
Net income
-$32.42M
Gross margin
100%
Net margin
-3,320.1%
The revenue has surged by 88% year-on-year and by 23% since the previous quarter
The gross profit has soared by 88% YoY and by 23% QoQ
The company's operating margin rose by 50% YoY and by 24% QoQ
VNRX's net margin is up by 48% YoY and by 24% QoQ
Growth
What is Volitionrx's growth rate over time
Valuation
What is Volitionrx stock price valuation
P/E
N/A
P/B
N/A
P/S
55.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.64
The company's EPS rose by 29% YoY and by 13% QoQ
The equity is down by 40% since the previous quarter
The stock's P/S is 99% below its 5-year quarterly average of 4529.1 and 20% below its last 4 quarters average of 69.4
The revenue has surged by 88% year-on-year and by 23% since the previous quarter
Efficiency
How efficient is Volitionrx business performance
The company's return on sales rose by 48% YoY and by 24% QoQ
Volitionrx's ROA has decreased by 10% from the previous quarter and by 8% YoY
Dividends
What is VNRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VNRX.
Financial health
How did Volitionrx financials performed over time
The company's total assets is 64% lower than its total liabilities
The quick ratio has plunged by 81% YoY and by 47% from the previous quarter
VNRX's current ratio has dropped by 79% year-on-year and by 44% since the previous quarter
VNRX's debt is 127% higher than its equity
The company's debt to equity has shrunk by 134% YoY but it rose by 25% QoQ
The equity is down by 40% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.